Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Apr 04, 2013 4:29pm
319 Views
Post# 21212589

RE: What's Next???

RE: What's Next???

Nice summary of the projected milestones SanFran. Though I am guessing that some or all of your #9 thru #12 will come within the next 5 weeks. I have high hopes that the May 1- May 10 timeframe will be window of time for annoucements. I primarily believe this because of the ATVB conference is May 1-3 and is on RVX's agenda, and Peter Young has a scheduled talke at the Epigenetics in Drug Discovery meeting May 8-10. I wouldn't be too hopeful of them having any press releases before then other than ASSURE dosing completion.

My gut feeling is that they will keep the Fortress tightly guarded until beginning of May, at which time they will not only release topline ASSURE data, but will reveal the full results of SUSTAIN trial. There may even be a SUSTAIN manuscript ready to publish that is being embargoed until the ATVB meeting. Perhaps their attendance at ATVB is to give formal presentation of SUSTAIN data, coinciding with their press release of their top-line ASSURE results and publication of SUSTAIN data. Kind of like a one-two punch.

GLTA. 

 

Bullboard Posts